Steven Norton Cohen, MD
Ophthalmology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Office
- 1
- Since medical school
- 52 years
- Js Weill Medical College, Cornell University, 1974
Offices
1 location · San Francisco Eye Institute Inc · 10 clinicians in this group
Looking this up.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Cohen’s office at (415) 421-8667 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Original Medicare doctor bills
$28,814
Medicare paid this office $28,814 for 193 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Established patient complete exam of visual system | 70 | $7,937 | $110 |
| Established patient problem focused exam of visual system | 46 | $6,252 | $82 |
| Return visit (30+ min) | 42 | $3,927 | $91 |
| New patient complete exam of visual system | 36 | $3,767 | $105 |
| Exam of visual field with extended testing | 18 | $1,117 | $59 |
See all 6 services
| Established patient complete exam of visual system | 70 | $7,937 | $110 |
| Established patient problem focused exam of visual system | 46 | $6,252 | $82 |
| Return visit (30+ min) | 42 | $3,927 | $91 |
| New patient complete exam of visual system | 36 | $3,767 | $105 |
| Exam of visual field with extended testing | 18 | $1,117 | $59 |
| Imaging of optic nerve | 14 | $469 | $34 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
193 Original Medicare patients in 2024. Average age 76 · Women 54% · Also on Medicaid 14% · Health risk score 0.93. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 62% · Diabetes 21% · Coronary heart disease 20% · Chronic kidney disease 18% · Cancer 15% · Depression 13% · Atrial fibrillation 12% · COPD 9% · Dementia 8% · Heart failure 6%.
The office billed $72,962, Medicare allowed $43,102 and paid $28,814; for 316 services of 23 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 193 | 316 | 76 | 0.93 | $72,962 | $28,814 |
| 2023 | 168 | 282 | 76 | 0.91 | $59,536 | $24,199 |
| 2022 | 167 | 256 | 75 | 0.84 | $52,127 | $21,828 |
| 2021 | 189 | 297 | 75 | 0.83 | $63,645 | $26,500 |
| 2020 | 135 | 239 | 75 | 0.84 | $54,836 | $19,533 |
| 2019 | 169 | 299 | 76 | 1.00 | $68,195 | $25,938 |
| 2018 | 168 | 298 | 75 | 0.98 | $71,053 | $25,380 |
| 2017 | 177 | 292 | 76 | 1.08 | $69,470 | $27,188 |
| 2016 | 273 | 461 | 75 | 0.97 | $95,135 | $43,514 |
| 2015 | 254 | 460 | 75 | 1.17 | $92,075 | $44,395 |
| 2014 | 198 | 326 | 77 | 1.06 | $62,112 | $31,496 |
| 2013 | 232 | 398 | 76 | 1.04 | $110,586 | $38,254 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Return visit (30+ min) | 84 | $8,648 | $99 |
| Short return visit (20+ min) | 37 | $3,462 | $58 |
| Established patient complete exam of visual system | 25 | $3,120 | $125 |
| Established patient problem focused exam of visual system | 21 | $2,055 | $89 |
| New patient visit (45+ min) | 14 | $1,545 | $110 |
| Exam of visual field with extended testing | 21 | $1,133 | $54 |
| Imaging of optic nerve | 18 | $570 | $32 |
2022: 5 services
| Return visit (30+ min) | 87 | $8,988 | $103 |
| Short return visit (20+ min) | 49 | $5,743 | $69 |
| New patient visit (45+ min) | 30 | $3,960 | $132 |
| Exam of visual field with extended testing | 16 | $804 | $50 |
| Imaging of optic nerve | 17 | $537 | $32 |
2021: 4 services
| Return visit (30+ min) | 111 | $11,506 | $101 |
| Short return visit (20+ min) | 50 | $6,750 | $83 |
| New patient visit (45+ min) | 29 | $3,662 | $126 |
| Exam of visual field with extended testing | 11 | $539 | $49 |
2020: 4 services
| Established patient complete exam of visual system | 85 | $8,888 | $95 |
| Established patient problem focused exam of visual system | 38 | $5,028 | $72 |
| New patient complete exam of visual system | 17 | $1,583 | $93 |
| Exam of visual field with extended testing | 14 | $872 | $62 |
2019: 5 services
| Established patient complete exam of visual system | 117 | $11,522 | $94 |
| Established patient problem focused exam of visual system | 53 | $8,973 | $79 |
| New patient complete exam of visual system | 14 | $2,019 | $144 |
| Exam of visual field with extended testing | 17 | $1,188 | $63 |
| Imaging of optic nerve | 11 | $440 | $34 |
2018: 4 services
| Established patient complete exam of visual system | 118 | $12,249 | $94 |
| Established patient problem focused exam of visual system | 52 | $6,762 | $68 |
| New patient complete exam of visual system | 22 | $2,449 | $111 |
| Exam of visual field with extended testing | 17 | $1,341 | $61 |
2017: 5 services
| Established patient complete exam of visual system | 130 | $14,071 | $101 |
| Established patient problem focused exam of visual system | 43 | $5,489 | $80 |
| New patient complete exam of visual system | 11 | $1,299 | $118 |
| Short return visit (20+ min) | 14 | $1,030 | $57 |
| Short return visit | 12 | $632 | $42 |
2016: 4 services
| Long return visit (40+ min) | 173 | $19,580 | $109 |
| Short return visit (20+ min) | 73 | $10,489 | $59 |
| New patient visit (60+ min) | 47 | $7,802 | $166 |
| Return visit (30+ min) | 18 | $1,399 | $78 |
2015: 3 services
| Long return visit (40+ min) | 178 | $22,213 | $116 |
| Short return visit (20+ min) | 70 | $11,454 | $62 |
| New patient visit (60+ min) | 32 | $5,591 | $175 |
2014: 3 services
| Long return visit (40+ min) | 125 | $14,975 | $114 |
| Short return visit (20+ min) | 65 | $8,556 | $65 |
| New patient visit (60+ min) | 32 | $5,383 | $168 |
2013: 5 services
| Long return visit (40+ min) | 125 | $13,412 | $103 |
| Established patient complete exam of visual system | 50 | $5,546 | $109 |
| Short return visit (20+ min) | 61 | $5,305 | $51 |
| Established patient problem focused exam of visual system | 31 | $3,416 | $83 |
| New patient visit (60+ min) | 19 | $2,797 | $147 |
Drugs they prescribed that Part D paid
$24,533
Pharmacies billed $24,533 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 179) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
82 generic and 97 brand-name prescriptions · $24,533 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xiidra | 12 | $8,025 | $669 |
| Latanoprost | 80 | $1,193 | $15 |
| Dorzolamide-Timolol | 16 | $261 | $16 |
| Timolol Maleate | 11 | $141 | $13 |
Year by year
| 2024 | 179 | 50 | 0% (0) | 54% | $24,533 |
| 2023 | 176 | 53 | 0% (0) | 63% | $25,824 |
| 2022 | 231 | 61 | 0% (0) | 61% | $31,725 |
| 2021 | 227 | 56 | 0% (0) | 69% | $26,981 |
| 2020 | 257 | 53 | 0% (0) | 65% | $30,452 |
| 2019 | 323 | 60 | 0% (0) | 57% | $31,573 |
| 2018 | 351 | 67 | 0% (0) | 62% | $37,552 |
| 2017 | 446 | 76 | 0% (0) | 55% | $34,838 |
| 2016 | 514 | 97 | 0% (0) | 48% | $43,120 |
| 2015 | 563 | 99 | 0% (0) | 58% | $44,635 |
| 2014 | 603 | 96 | 0% (0) | 61% | $40,081 |
| 2013 | 551 | 91 | 0% (0) | 68% | $41,202 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Xiidra | 12 | $8,892 | $741 |
| Latanoprost | 74 | $2,059 | $28 |
| Dorzolamide-Timolol | 14 | $558 | $40 |
2022: 6 drugs
| Combigan | 11 | $5,173 | $470 |
| Lumigan | 17 | $4,580 | $269 |
| Latanoprost | 104 | $4,044 | $39 |
| Brimonidine | 12 | $678 | $56 |
| Dorzolamide-Timolol | 11 | $520 | $47 |
| Timolol Maleate | 15 | $96 | $6 |
2021: 5 drugs
| Lumigan | 15 | $4,351 | $290 |
| Simbrinza | 13 | $2,467 | $190 |
| Latanoprost | 91 | $2,431 | $27 |
| Dorzolamide-Timolol | 12 | $1,241 | $103 |
| Timolol Maleate | 17 | $225 | $13 |
2020: 8 drugs
| Xiidra | 11 | $6,332 | $576 |
| Azopt | 11 | $3,767 | $342 |
| Simbrinza | 18 | $3,337 | $185 |
| Combigan | 11 | $2,894 | $263 |
| Latanoprost | 108 | $1,986 | $18 |
| Brimonidine | 15 | $1,308 | $87 |
| Timolol Maleate | 19 | $245 | $13 |
| Erythromycin | 13 | $171 | $13 |
2019: 6 drugs
| Lumigan | 19 | $4,803 | $253 |
| Simbrinza | 23 | $3,732 | $162 |
| Brimonidine | 19 | $2,982 | $157 |
| Latanoprost | 158 | $2,739 | $17 |
| Dorzolamide-Timolol | 13 | $455 | $35 |
| Timolol Maleate | 26 | $387 | $15 |
2018: 8 drugs
| Lumigan | 27 | $7,826 | $290 |
| Combigan | 24 | $7,541 | $314 |
| Brimonidine | 16 | $3,135 | $196 |
| Latanoprost | 165 | $2,873 | $17 |
| Simbrinza | 16 | $2,391 | $149 |
| Dorzolamide | 15 | $443 | $30 |
| Dorzolamide-Timolol | 15 | $371 | $25 |
| Timolol Maleate | 22 | $283 | $13 |
2017: 6 drugs
| Lumigan | 36 | $9,711 | $270 |
| Combigan | 19 | $4,382 | $231 |
| Latanoprost | 245 | $4,056 | $17 |
| Simbrinza | 11 | $2,903 | $264 |
| Dorzolamide-Timolol | 38 | $1,110 | $29 |
| Timolol Maleate | 31 | $406 | $13 |
2016: 7 drugs
| Lumigan | 36 | $12,784 | $355 |
| Combigan | 23 | $5,654 | $246 |
| Latanoprost | 256 | $3,965 | $15 |
| Pataday | 11 | $3,186 | $290 |
| Simbrinza | 14 | $2,285 | $163 |
| Dorzolamide-Timolol | 30 | $865 | $29 |
| Timolol Maleate | 39 | $488 | $13 |
2015: 11 drugs
| Lumigan | 43 | $10,978 | $255 |
| Combigan | 32 | $5,857 | $183 |
| Restasis | 13 | $4,978 | $383 |
| Travatan Z | 16 | $3,474 | $217 |
| Latanoprost | 263 | $3,464 | $13 |
| Pataday | 15 | $3,424 | $228 |
| Simbrinza | 16 | $2,259 | $141 |
| Alphagan P | 12 | $1,521 | $127 |
| Dorzolamide-Timolol | 38 | $1,017 | $27 |
| Timolol Maleate | 44 | $429 | $10 |
| Erythromycin | 13 | $187 | $14 |
2014: 9 drugs
| Lumigan | 36 | $8,237 | $229 |
| Combigan | 48 | $6,490 | $135 |
| Latanoprost | 269 | $4,205 | $16 |
| Alphagan P | 23 | $2,800 | $122 |
| Travatan Z | 15 | $2,048 | $137 |
| Pataday | 14 | $1,975 | $141 |
| Dorzolamide-Timolol | 38 | $1,484 | $39 |
| Timolol Maleate | 60 | $624 | $10 |
| Erythromycin | 12 | $181 | $15 |
2013: 13 drugs
| Lumigan | 39 | $7,573 | $194 |
| Restasis | 11 | $5,466 | $497 |
| Combigan | 40 | $5,430 | $136 |
| Latanoprost | 221 | $4,575 | $21 |
| Travatan Z | 18 | $2,371 | $132 |
| Pataday | 18 | $2,281 | $127 |
| Azopt | 13 | $1,941 | $149 |
| Dorzolamide-Timolol | 45 | $1,919 | $43 |
| Tobradex | 11 | $1,795 | $163 |
| Alphagan P | 14 | $1,784 | $127 |
| Brimonidine | 15 | $1,301 | $87 |
| Timolol Maleate | 36 | $427 | $12 |
| Prednisolone Acetate | 16 | $355 | $22 |
Money from drug and device companies
$180 in 2025
| 2025 | 4 | 5 | None | $180 |
| 2024 | 1 | 1 | None | $25 |
| 2023 | 3 | 4 | None | $119 |
| 2022 | 3 | 3 | None | $60 |
| 2021 | 2 | 3 | None | $70 |
| 2020 | 1 | 1 | None | $18 |
| 2019 | 5 | 7 | None | $752 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Apellis Pharmaceuticals | None | $68 | 1 payment
|
| Glaukos | Kxl System (Not Refurbished) | $56 | 2 payments
|
| Harrow Eye | Vevye | $35 | 1 payment
|
| Bausch & Lomb Americas | Miebo | $21 | 1 payment
|
See all 5 published payments
| Glaukos | Meals · 2025-12-11 | Photrexa Viscous and Photrexa | $27 |
| Glaukos | Meals · 2025-10-30 | Kxl System (Not Refurbished) | $29 |
| Apellis Pharmaceuticals | Meals · 2025-10-17 | None | $68 |
| Bausch & Lomb Americas | Meals · 2025-07-10 | Miebo | $21 |
| Harrow Eye | Meals · 2025-04-29 | Vevye | $35 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $25
| RxSight | Rxsight Contact Lens | $25 | 1 payment
|
2023: $119
| AbbVie | Durysta | $69 | 2 payments
|
| Horizon Therapeutics plc | Tepezza | $26 | 1 payment
|
| Alcon Vision | Clareon | $24 | 1 payment
|
2022: $60
| Novartis Pharmaceuticals | Xiidra | $24 | 1 payment
|
| Horizon Therapeutics plc | Tepezza | $19 | 1 payment
|
| Dompe US | Oxervate | $18 | 1 payment
|
2021: $70
| Bausch & Lomb a division of Bausch Health US | Lotemax Sm | $47 | 2 payments
|
| Aerie Pharmaceuticals | Rocklatan | $24 | 1 payment
|
2020: $18
| Sun Pharmaceutical Industries | Cequa | $18 | 1 payment
|
2019: $752
| Bausch & Lomb a division of Bausch Health US | Vyzulta | $241 | 2 payments
|
| Aerie Pharmaceuticals | None | $155 | 1 payment
|
| Allergan | Lumigan | $125 | 2 payments
|
| Sun Pharmaceutical Industries | Cequa | $116 | 1 payment
|
| Kala Pharmaceuticals | Inveltys | $116 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 82.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1306947643
- Licence
- CA G367470
- Trained
- Js Weill Medical College, Cornell University, 1974 · 52 years ago
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 3838 California St, Suite 116, San Francisco, CA, 94118
- NPI first listed
- 2006-09-26
- NPI last updated
- 2010-06-22
This is when the NPI record was last certified, not a medical board exam.